Merck & Co. Convertible Preferred Stock Authorized Shares remained flat by 0.0% to 20M in Q4 2025 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from 20M to 20M. Over 5 years (FY 2020 to FY 2025), Convertible Preferred Stock Authorized Shares shows relatively stable performance with a 0.0% CAGR.
High authorization levels provide flexibility for future capital raises but may signal potential future dilution for common shareholders.
This represents the maximum number of shares of convertible preferred stock that the company is legally permitted to iss...
Standard corporate governance disclosure found in the equity section of the balance sheet.
convertible_preferred_stock_authorized_shares| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|---|
| Value | 20M | 20M | 20M | 20M | 20M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +0.0% |
| YoY Change | — | +0.0% | +0.0% | +0.0% | +0.0% |